Targeted agents have improved the efficacy of chemotherapy for cancer patients, however,
there remains a lack of understanding of how these therapies affect the unsuspecting …

Somatic mutations of epidermal growth factor receptor (EGFR) occur in~ 3% of colorectal
cancer (CRC) patients. Here, through systematic functional screening of 21 recurrent EGFR …

Gastroesophageal adenocarcinomas (GEA) are devastating diseases with stark global
presence. Over the past 10 years, there have been minimal improvements in treatment …

Molecular targeted therapy is expected to be a promising therapeutic approach for the
treatment of esophageal squamous cell carcinoma (ESCC); however, the gene amplification …

Importance Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is
frequently due toRASandEGFRextracellular domain (ECD) mutations in metastatic …

Acquired resistance to epidermal growth factor receptor (EGFR) targeted antibodies
represents a clinical challenge in the treatment of gastrointestinal tumors such as metastatic …

Epidermal growth factor receptor (EGFR) is a validated target in different human
malignancies. EGFR tyrosine kinase inhibitors (TKIs) are known to contribute considerably …

The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG)
cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired …

Purpose To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin
(CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 …

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in
homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With …